Falcons' Fortunes - FACIT's Annual Pitch Competition
Opportunity for Ontario Cancer Researchers to vie for the
"Ernsting Entrepreneurship Award"
Falcons' Fortunes (based on the popular TV series Dragons' Den) invites Ontario-based entrepreneurs working in the oncology space to pitch innovative research ideas to an external panel of judges.
Hosted by the FACIT Falcons (i.e. the FACIT team), this annual event offers $50,000 in Prospects funding to invest in the most promising oncology research idea. While the research idea should be novel and sound, the competition is for the best pitch i.e. the presentation that best convinces the investor judging panel on the value of the idea and how $50,000 would improve and/or better illustrate the potential, and if possible commercial, value of the innovative idea itself.
The Falcons’ Fortunes event endeavors to enhance, support and celebrate a culture of commercialization in Ontario, such as the cultivation of skill sets that enable ideas to be successfully pitched to investors and promotion of entrepreneurial spirit.
The Falcons’ Fortunes pitch competition is open to any Ontario-based entrepreneurial researcher (e.g. academia, research institutions, research hospitals, startups, etc.) working in the oncology space. Basically, anyone with the entrepreneurial itch should participate!
How to participate:
The next call to participate will be issued in November 2021.
Bridge7 uses AI to automate & improve the efficiency, consistency & quality of delivering cancer care. Bridge7 has commercialized the first automated treatment planning solution being used clinically.
Recognizing a real unmet need, Xpan is developing expandable surgical access ports that aim to increase safety and efficiency of minimally invasive surgeries.
ReFilx™ is a novel polymeric soft tissue filler that provides breast cancer patients with a cosmetically superior, minimally-invasive and cost-effective solution for the permanent restoration of breast defects following lumpectomy.
2017: Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer
The novel platform delivers sustained and amplified viral-mediated cell killing specific to pancreatic cancer (PCa) via the production of PCa cell-targeted amiR-containing exosomes.